Unigestion Holding SA Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Unigestion Holding SA purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, HoldingsChannel.com reports. The firm purchased 2,199 shares of the medical research company’s stock, valued at approximately $521,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FMR LLC grew its holdings in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of IQVIA during the 3rd quarter worth approximately $147,683,000. 1832 Asset Management L.P. lifted its holdings in shares of IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after buying an additional 376,595 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of IQVIA in the second quarter valued at approximately $70,610,000. Finally, Impax Asset Management Group plc lifted its holdings in IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after acquiring an additional 264,555 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $201.05 on Thursday. The company has a market cap of $36.49 billion, a P/E ratio of 26.38, a P/E/G ratio of 2.08 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm’s 50 day moving average is $214.01 and its two-hundred day moving average is $224.77. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a report on Wednesday. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Barclays decreased their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Redburn Atlantic began coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. Finally, Robert W. Baird dropped their price target on IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $257.87.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.